Drug Type ASO |
Synonyms 2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA |
Target |
Action inhibitors |
Mechanism PLP1 inhibitors(proteolipid protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pelizaeus-Merzbacher Disease | Preclinical | United States | 01 Jul 2020 |





